Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T20:21:00.622Z.
Calculation as of: 2026-10-06T20:21:00.622Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b8816454c8f8663c3bedc847144af8f107147f6cc2e90a46c8541497c2a45775
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$5.52B
EBITDA Yield
3.26%
TTM Avg
3.04%
3Y Avg
3.04%
5Y Avg
3.04%
Market Cap
$5.87B
EBITDA Yield
1.79%
TTM Avg
1.65%
3Y Avg
1.60%
5Y Avg
1.99%
Market Cap
$5.32B
EBITDA Yield
3.46%
TTM Avg
10.75%
3Y Avg
10.29%
5Y Avg
10.29%
Market Cap
$5.95B
EBITDA Yield
2.22%
TTM Avg
1.62%
3Y Avg
2.24%
5Y Avg
4.65%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CG Oncology Inc. (CGON) | $5.61B | N/A | N/A | N/A | N/A |
| RadNet, Inc. (RDNT)vs › | $5.53B | 4.61% | 4.21% | 4.87% | 6.47% |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.52B | 3.26% | 3.04% | 3.04% | 3.04% |
| Kodiak Sciences Inc. (KOD)vs › | $5.78B | N/A | N/A | N/A | N/A |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.79B | N/A | N/A | N/A | N/A |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.87B | 1.79% | 1.65% | 1.60% | 1.99% |
| GRAIL Inc. (GRAL)vs › | $5.89B | N/A | N/A | N/A | N/A |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.32B | 3.46% | 10.75% | 10.29% | 10.29% |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.95B | 2.22% | 1.62% | 2.24% | 4.65% |
| CRISPR Therapeutics AG (CRSP)vs › | $5.21B | N/A | 8.18% | 5.23% | 5.23% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
